Grifols SA (GRLS)

Real-time derived
Currency in EUR
9.000
+0.396(+4.60%)
Closed·
GRLS Scorecard
Full Analysis
High shareholder yield
GRLS is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
8.6149.066
52 wk Range
7.32411.350
Key Statistics
Edit
Prev. Close
9
Open
8.716
Day's Range
8.614-9.066
52 wk Range
7.324-11.35
Volume
2.52M
Average Vol. (3m)
1.56M
1-Year Change
-8.96%
Book Value / Share
8.29
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
GRLS Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
15.619
Upside
+73.55%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year
Show more

Grifols SA Company Profile

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma, and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factor VIII/von Willebrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease. It also markets diagnostic testing equipment, reagents, and other equipment; offers biological products and manufacturing services; and manufactures and sells plasma to third parties. In addition, the company offers Yimmugo IDP, an immunology drug; Yimmugo PTI, a hematology drug; and Prolastin vials, a pulmonology drug. Further, it develops Xembify Pre-filled syringes, Gamunex Bags, and FlexBag; Xembify Biweekly dosing, Fibrinogen, and VISTASEAL; Prolastin-C AADT and Fostamatinib; Xembify – CLL, Albumina 20% and 5%, and Trimodulin; Alfa-1 AT 15%, GRF6019, GRF6021, Aßvac402, AKST4290, and AKST4290; GIGA 2339 and GIGA564; and recIG, Alfa-1 AT - in non-cystic fibrosis bronchiectasis, and OSIG that are in pre-clinical stage. It has collaboration agreements with Canadian Blood Services to supply grains of Immunoglobulin. The company was founded in 1909 and is headquartered in Barcelona, Spain.

Employees
23800
Market
Spain

Compare GRLS to Peers and Sector

Metrics to compare
GRLS
Peers
Sector
Relationship
P/E Ratio
28.7x22.2x−0.5x
PEG Ratio
-0.470.00
Price / Book
1.0x2.3x2.6x
Price / LTM Sales
0.8x3.1x3.0x
Upside (Analyst Target)
83.3%45.9%53.7%
Fair Value Upside
Unlock16.9%8.4%Unlock

Analyst Ratings

10 Buy
2 Hold
1 Sell
Ratings:
13 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 15.619
(+73.55% Upside)

Earnings

Latest Release
May 12, 2025
EPS / Forecast
0.12 / 0.1581
Revenue / Forecast
1.79B / 1.72B
EPS Revisions
Last 90 days

People Also Watch

2.7310
SABE
+0.85%
11.790
REP
+1.11%
7.500
CABK
+0.81%
31.200
IDR
+1.04%
26.500
ELE
+1.07%

FAQ

What Is the Grifols (GRLS) Stock Price Today?

The Grifols stock price today is 9.00

What Stock Exchange Does Grifols Trade On?

Grifols is listed and trades on the Madrid Stock Exchange stock exchange.

What Is the Stock Symbol for Grifols?

The stock symbol for Grifols is "GRLS."

What Is the Grifols Market Cap?

As of today, Grifols market cap is 5.60B.

What Is Grifols's Earnings Per Share (TTM)?

The Grifols EPS (TTM) is 0.29.

When Is the Next Grifols Earnings Date?

Grifols will release its next earnings report on Jul 24, 2025.

From a Technical Analysis Perspective, Is GRLS a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.